Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Comorbidity Affects the Relationship Between Glycemic Control and Cardiovascular Outcomes in Diabetes: A Cohort Study

Greenfield, Sheldon, Billimek, John, Pellegrini, Fabio, Franciosi, Monica, De Berardis, Giorgia, Nicolucci, Antonio, Kaplan, Sherrie H. · 2009 · Annals of Internal Medicine

Abstract

BACKGROUND: Recent studies have shown mixed results regarding the effectiveness of intensive glucose-lowering therapy in reducing risk for cardiovascular events. OBJECTIVE: To determine whether attaining hemoglobin A(1c) (HbA(1c)) targets of 6.5% or less or 7.0% or less for glycemic control at baseline provides differential benefits for patients with high versus low-to-moderate levels of comorbidity. DESIGN: 5-year longitudinal observational study of patients with type 2 diabetes. Patients were categorized into high and low-to-moderate comorbidity subgroups by using the Total Illness Burden Index (TIBI), a validated patient-reported measure of comorbidity. SETTING: 101 diabetes outpatient clinics and 103 general practitioners' clinics in Italy. PATIENTS: 2613 (83%) of 3074 patients with type 2 diabetes, sampled randomly from diabetes outpatient clinic rosters and recruited consecutively from general practitioners' clinics, who completed the baseline questionnaire. MEASUREMENTS: TIBI score, total mortality, and incident cardiovascular events. Hazard ratios (HRs) were adjusted for age and sex. RESULTS: Attaining an HbA(1c) level of 6.5% or less at baseline was associated with lower 5-year incidence of cardiovascular events in the low-to-moderate comorbidity subgroup (adjusted HR, 0.60 [95% CI, 0.42 to 0.85]; P = 0.005) but not in the high comorbidity subgroup (adjusted HR, 0.92 [CI, 0.68 to 1.25]; P = 0.61; P for subgroup by HbA(1c) interaction = 0.048). Similarly, attaining a baseline HbA(1c) level of 7.0% predicted fewer cardiovascular events in the low-to-moderate comorbidity subgroup (adjusted HR, 0.61 (CI, 0.44 to 0.83; P = 0.001) but not in the high comorbidity subgroup (adjusted HR, 0.88 [CI, 0.66 to 1.17]; P = 0.38; P for subgroup by HbA(1c) interaction = 0.093). LIMITATIONS: The observational nature of the study does not allow causal inference. The length of the data collection period was limited. Information on clinical management was not available. CONCLUSION: Patients with the high levels of comorbidity common in type 2 diabetes may receive diminished cardiovascular benefit from intensive blood glucose control. Comorbidity should be considered when tailoring glucose-lowering therapy in patients with type 2 diabetes. PRIMARY FUNDING SOURCE: Pfizer of Italy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-151-12-200912150-00005

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 170

Metadata

Authors
Greenfield, S., Billimek, J., Pellegrini, F., Franciosi, M., De Berardis, G., Nicolucci, A., & Kaplan, S. H.
Venue
Annals of Internal Medicine
Published
2009-12-15
Volume
151
Issue
12
Pages
854-860
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W1967539655
Cited by
170
References
8
FWCI
14.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comorbidity Affects the Relationship Between Glycemic Control and Cardiovascular Outcomes in Diabetes: A Cohort Study. https://app.cochat.ai/papers/10.7326/0003-4819-151-12-200912150-00005
The paper
Greenfield, S., Billimek, J., Pellegrini, F., Franciosi, M., De Berardis, G., Nicolucci, A., & Kaplan, S. H. (2009). Comorbidity Affects the Relationship Between Glycemic Control and Cardiovascular Outcomes in Diabetes: A Cohort Study. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-151-12-200912150-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.